This article has been corrected to reflect that Euclidean Capital is not an investor in Celmatix.

NEW YORK (GenomeWeb) – Women's reproductive health company Celmatix is poised to expand its business next year, betting on a combination of genetic testing and predictive clinical data analysis to help women and their doctors make choices related to having children and treating infertility.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.